Akcea Therapeutics

Clinical trials sponsored by Akcea Therapeutics, explained in plain language.

Now part of Ionis Pharmaceuticals, Inc. IONS NASDAQ

A subsidiary of Ionis Pharmaceuticals, focused on developing RNA-targeted therapies for cardiovascular and metabolic diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

New study tracks Real-World safety of TEGSEDI for rare nerve disease

Knowledge-focused Ongoing

This study follows 240 patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) to monitor the long-term safety of the drug TEGSEDI. Researchers will compare patients who have taken TEGSEDI with those who have not, focusing on side effects like low platel…

Sponsor: Akcea Therapeutics • Aim: Knowledge-focused

Last updated Jul 31, 2026 00:00 UTC

Akcea Therapeutics

New study tracks Real-World safety of TEGSEDI for rare nerve disease